Ensysce Biosciences welcomes positive bioequivalence study data of novel ‘TAAP’ drug PF614

Ensysce Biosciences CEO Dr Lynn Kirkpatrick says she’s encouraged by position bioequivalence study data of the company’s novel Trypsin-Activated Abuse-Protected (TAAP) drug, PF614.

Kirkpatrick told Proactive that the study follows the successful completion of the multi-ascending twice-daily dosing study of PF614 and compared the release of oxycodone from PF614 versus OxyContin administered to subjects in both fasted and fed states.

She also discussed the company’s Multi-Pill Abuse Resistance (MPAR) platform and outlined the steps to commercialization of safer prescription drugs.

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews